Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0MR0B
|
|||
| Former ID |
DIB005520
|
|||
| Drug Name |
TEW-7197
|
|||
| Synonyms |
Vactosertib
Click to Show/Hide
|
|||
| Indication | Myeloproliferative neoplasm [ICD-11: 2A20; ICD-10: D47.7] | Phase 2 | [1] | |
| Urothelial carcinoma [ICD-11: 2C92.0] | Phase 2 | [2] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1/2 | [3] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [4] | ||
| Company |
Medpacto
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H18FN7
|
|||
| Canonical SMILES |
CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4
|
|||
| InChI |
1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)
|
|||
| InChIKey |
FJCDSQATIJKQKA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1352608-82-2
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04103645) Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04064190) Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT02160106) First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors. U.S. National Institutes of Health. | |||
| REF 5 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.